NCT07331545
Not yet recruiting
Phase 1
A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Ascending Doses of QL2401 in Healthy Chinese Adult Participants
Overview
- Phase
- Phase 1
- Status
- Not yet recruiting
- Enrollment
- 70
- Primary Endpoint
- Incidence and severity of adverse events
Overview
Brief Summary
This is a first-in-human, Phase I, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of QL2401 following single and multiple ascending subcutaneous doses in healthy Chinese adults. The study consists of two parts: single ascending dose (SAD) and multiple ascending dose (MAD). Participants will be randomly assigned to receive either QL2401 or placebo. The primary objective is to assess safety and tolerability. Secondary objectives include evaluation of PK parameters in SAD & MAD; exploratory objectives include assessment of PD biomarkers and immunogenicity.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 45 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy male and female participants, aged 18 to 45 years at the time of screening.
- •Body weight of males should be ≥50.0kg and body weight of females should be≥45.0kg, BMI 18.5-32.5 kg/m² (Including boundary values)at the time of screening.
- •During the screening and baseline periods, participants with normal laboratory tests, vital sign measurements, physical examination results, 12-lead electrocardiogram, and abdominal B-ultrasound results, or those with abnormalities judged by the investigators as having no clinical significance (MAD section: those with clinically significant lipid indicators and abdominal B-ultrasound results but meeting the following criteria can be included: TC\< 7.2mmol/L, LDL-C\< 4.9mmol/L, TG\< 4.52mmol/L; Abdominal B-ultrasound indicates mild or moderate fatty liver).
- •Participants voluntarily signed the informed consent form before the trial.
- •Willing to use contraception and comply with study procedures.
Exclusion Criteria
- •Serious, progressive, and uncontrolled diseases, including but not limited to the cardiovascular system, endocrine and metabolic system, immune system, urinary system, digestive system, respiratory system, blood system, gynecological system, nervous system, mental system, and musculoskeletal system, and the researcher determines that the participant is not suitable for this trial;
- •Serious or chronic recurrent gastrointestinal diseases (such as chronic diarrhea, active ulcer, reflux esophagitis), or screening before 12 weeks underwent gastrointestinal surgery;
- •History of acute or chronic pancreatitis, history of symptomatic gallbladder, pancreas injury can lead to high risk factors of acute pancreatitis, or screening blood amylase \> 1.5 x upper limit of normal range (ULN);
- •Type 1 diabetes, type 2 diabetes or other types of diabetes;
- •Abnormal liver, renal, or cardiac function
- •Positive for hepatitis B, C, HIV, or syphilis
- •Pregnant or breastfeeding women
- •History of drug or alcohol abuse
- •Use of prescription drugs within 2 weeks prior to dosing
- •According to the researcher's judgment, it may increase the risks related to the research, may interfere with the interpretation of the research results.
Arms & Interventions
QL2401
Experimental
Intervention: QL2401 (Drug)
Placebo
Placebo Comparator
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Incidence and severity of adverse events
Time Frame: From baseline up to 29 days after last dose (SAD) or 57 days after last dose(MAD)
Safety and tolerability as assessed by the incidence and severity.
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Not yet recruiting
Not Applicable
Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile DysfunctionNCT07311330Beijing Inno Medicine Co., Ltd.40
Active, not recruiting
Phase 2
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes MellitusNCT07321678Ascletis Pharma (China) Co., Limited100
Active, not recruiting
Phase 1
Phase I Study of PollenVax in Patients With Mugwort Pollen-Induced Allergic RhinitisNCT07317960Kazakh National Agrarian University30
Recruiting
Phase 2
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes MellitusNCT07282743Sun Pharmaceutical Industries Limited285
Recruiting
Phase 1
Inhaled RB042 in Healthy Adult Volunteers and Healthy Adult SmokersNCT07285122RAGE Bio90